In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Nurix Therapeutics (NRIX – Research Report), with a price target of $36.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Robert Burns has given his Buy rating due to a combination of factors related to the promising clinical data presented by Nurix Therapeutics. At the European Hematology 2025 annual meeting, Nurix showcased results from its BTK degrader, NX-5948, which is in Phase 1a/1b trials for patients with relapsed or refractory B-cell malignancies. The data revealed an impressive overall response rate (ORR) of 80.9% in chronic lymphocytic leukemia (CLL) patients, with notable response rates at various dosage levels, indicating the drug’s potential efficacy.
Additionally, the treatment showed an 84.2% ORR in patients with Waldenstrom macroglobulinemia, with responses deepening over time. The safety profile was manageable, with some occurrences of neutropenia, thrombocytopenia, and anemia, but no new cases of atrial fibrillation. These promising results, alongside the need for further follow-up to understand progression-free survival, support the reiterated Buy rating and a 12-month price target of $36.
In another report released on June 27, Oppenheimer also reiterated a Buy rating on the stock with a $32.00 price target.